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Abstract The synthesis and secretion of the gonadotropic
hormones involves coordination of signal transduction,
gene expression, protein translation, post-translational
folding and modification and finally secretion. The produc-
tion of biologically active gonadotropin thus requires
appropriately folded and glycosylated subunits that assem-
ble to form the heterodimeric hormone. Here we overview
recent literature on regulation of gonadotropin subunit gene
expression and current understanding of the assembly and
secretion of biologically active gonadotropic hormones.
Finally, we discuss the therapeutic potential of understand-
ing glycosylation function towards designing new forms of
gonadotropins based on observations of physiologically
relevant parameters such as age related glycosylation
changes.
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The glycoprotein hormone family includes luteinizing
hormone (LH), follicle-stimulating hormone (FSH),
thyroid-stimulating hormone (TSH) and chorionic gonado-
tropin (CG) [1]. Production of these hormones occurs in
either the pituitary (LH, FSH, TSH) [2] or by the chorion of
a developing fetus (CG) [3, 4]. These hormones are
heterodimeric, consisting of a common alpha subunit and
a unique beta subunit (Fig. 1) ,a n dt h e ya r ea l s o
glycosylated [5]. Therefore, their production requires
coordination of transcriptional regulation of the subunit
genes [6], translation of mRNA, post-translational process-
ing and assembly, packaging and secretion.
2 Regulation of the gonadotropin genes
The canonical regulator of gonadotropin secretion is the
hypothalamic decapeptide, GnRH, which can induce
stimulus-secretion coupling as well as gene expression
[7]. However, it is clear now that many paths coalesce to
achieve the complexity and disparate regulation of LH and
FSH expression, a necessary first step to production and
secretion. GnRH mediated gonadotropin secretion can be
enhanced by the transcription factor Isl-1, which is elevated
in response to GnRH as well as by activin and leptin
stimulation, although the responses to activin and leptin
were higher and more prolonged than that induced by
GnRH. However, subsequent experiments indicated Isl-1
mainly is responsible for leptin-mediated FSHβ and LHβ
production, not GnRH- or activin-mediated secretion, as
knocking down Isl-1 expression had no significant effect on
gonadotropin regulation by either GnRH or activin [8].
Despite this regulation, in marsupials, LHβ gene expression
is relatively unchanged despite widely variable levels of LH
secretion, whereas FSHβ gene expression covaries with
level of FSH [9]. Thus, the secretion of LH appears to be
induced, whereas the secretion of FSH is constitutive, as
will be discussed below.
The release of GnRH from hypothalamic neurons is
pulsatile [10]. Given the effect of GnRH as a releasing
Fig. 1 Primary structures of vertebrate gonadotropins. The mature
amino acid sequences for the human gonadotropin subunits and equine
LH/CGβ are shown along with those predicted by the SignalP 3.0 Server
(http://www.cbs.dtu.dk/services/SignalP/) for the primary structures
translated from nucleotide sequences. The amino acid sequences were
obtained from NCBI and represent selected vertebrate species:
mammalian (Homo sapiens), avian (Gallus gallus), reptilian (Anolis
carolinensis), amphibian (Xenopus laevis), and fish (Danio rerio)o f
clinical or scientific significance. The D. rerio FSHβ sequence is
suspect because of the lack of potential cystine noose disulfide bond.
The horse (Equus caballus) and squirrel monkey (Saimiri boliviensis
boliviensis)C G β sequences were included to illustrate alternatives to
the well known hCGβ primary structure and because they replace LHβ
in their respective species. Sequence alignments were made using the
NCBI tool, COBALT. The locations of N-glycans are indicated by the
“tuning forks” above the glycosylation sites. Please note that while both
FSHβ and hCGβ possess two N-glycans, most vertebrate LHβsa r e
typically glycosylated at Asn
13, while human LHβ is glycosylated at
Asn
30. The human CGb is also O-glycosylated at 4 Ser residues 121,
127, 132, and 138. Squirrel monkey CGβ is N-glycosylated at Asn
30
and O-glycosylation remains to be determined experimentally, although
they are expected to be absent. The three loops created by the cystine
knot motifs and the β-subunit seat belt loop are shaded and labeled. Cys
residues are highlighted by asterisks under subunit sequence. A. Alpha
subunit sequences illustrating the difference in numbering between the
92-residue human and other vertebrate 96-98-residue α-subunit sequen-
ces. B. Beta subunit sequences grouped by hormone as follows: LHβ,
FSHβ,a n dC G β
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GnRH would engender gene expression that would co-vary
with pulse. When mouse pituitary gonadotrophs were
stimulated with adenylate-cyclase-activating polypeptide
there was no change in LHβ or FSHβ gene expression,
although the common α subunit gene expression was
induced [11]. Remarkably, perfusion of pulsatile doses of
adenylate-cyclase-activating polypeptide engendered eleva-
tion of both the LHβ and FSHβ genes [11]. Although both
LHβ and FSHβ gene expression was upregulated by pulsed
administration of the peptide, high frequency pulses
increased LHβ gene expression more than FSHβ gene
expression whilst low frequency pulses had the opposite
effect [11]. Thus, like GnRH, differential regulation of
gonadotropin gene expression can be achieved by modula-
tion of the signal frequency. The control of LHβ gene
transcription by the transcription factor Early Growth
Response 1 (EGR1) led to the hypothesis that the
underpinning of the pulsed-dose differential regulation of
the LHβ and FSHβ genes was EGR1. However, GnRH-
induced JNK1 and MEK1 kinase activities, while essential,
do not control EGR1 gene expression in a pulsed manner
[12]. Another transcription factor, CREB, can bind to
cAMP response elements on the FSHβ gene promoter,
and could give rise to the differential pulse effect on
gonadotropin gene expression. In concert with this, it has
been demonstrated that high pulse frequency of GnRH does
give rise to elevated ICER, which would bind to CRE on
the FSHβ gene and dampen its transcription [13]. Thusly,
the induction of a negative regulatory transcription factor
could potentially provide a mechanism for the differential
regulation of gonadotropin gene expression under low and
high pulse frequency.
Although a mechanism for differential gonadotropin gene
expression, which can posit transcriptional factor dampening
of transcription is compelling, it also suggests that adenylate
cyclase is not the only downstream effector of GnRH. In this
regard, it has been shown quite elegantly that the prostaglan-
din biosynthetic pathway, and in particular PGF2α and PGI,
can regulate not only LHβ and FSHβ gene transcription, but
also the levels of GnRH receptor [14]. Such findings could
have translational value for the adjuvant treatment of
reproductive disease caused by gonadotropin imbalance and
requiring differential pharmacologic intervention.
Since 1976 evidence has been provided, which showed
the presence of the α subunit protein in non-pituitary and
non-placental tissues [15]. Adding to the list, it was recently
shown that HEK293 cells express high levels of α subunit
mRNA (500 fold) and protein (600 fold) in response to
elevation of cAMP caused by activation of transfected β-
adrenergic receptor [16]. However, not only cAMP is
involved because Gq-coupled receptor also induced expres-
sion of the α subunit. From these observations it is
reasonable to suggest that the expression of the α subunit
is not cell type dependent and the promoter likely embodies
cyclic AMP response element (CRE) binding sites for CRE
binding protein transcription factors. In addition, the control
of this promoter can also be anticipated to respond to
transcription factors that are regulated by intracellular levels
of calcium.
Of course, every reproductive physiologist knows that
castration gives rise to elevated gonadotropins in blood.
Indeed, as ovarian function wanes in mid-life, and gonadal
steroid production is decreased, FSH rises. Therefore, the
long loop feedback of gonadal steroids on gonadotropin
production was a harbinger of the potential for regulation of
gonadotropin gene expression by gonadal steroids. How-
ever, the regulation of gonadotropin secretion by proges-
terone was unanticipated. Progesterone increases FSHβ
gene expression but GnRH-induced LHβ gene expression
is repressed [17, 18]. Moreover, whereas induction of FSH
gene expression is due to progesterone receptor binding to
the promoter of the FSHβ gene, in the case of LHβ gene
regulation, progesterone receptor is not required [18].
Gonadal steroids also modulate neuronal firing and,
therefore, secretion of gonadotropins. For example, during
the estrous cycle, progesterone increases the locus coeru-
leus expression of fos related proteins and firing whereas in
high estrogen expression is lower and lowered fos related
antigen staining [19].
We would be remiss to not mention here that steroidal
control of gonadotropin secretion can also be mediated by
hypothalamic kisspeptin neurons controlling the release of
GnRH [20]. Along these lines, it is also important to
mention the hypothalamic factor, Gonadotropin Inhibitory
Hormone (GnIH or RFRP-1,-2,-3 peptides), which inhibits
release of gonadotropins mediated by GnRH [21]. Both
types of neurons are emerging as positive and negative
mediators of gonadal feedback, respectively, as well as
environmental regulators of GnRH neurons [22]. The GnIH
peptides, originally identified in avian species, have been
found in mammalian species in recent years, and studies are
in progress to confirm GnIH plays similar roles in
mammalian reproduction [21]. Co-localization studies have
shown 40–80% of GnRH neurons close to GnIH-positive
fibers, implying a direct effect on GnRH secretion. Animal
studies in rat, sheep, and cattle supported direct effects of
GnIH on gonadotropes, however, a negative result in rats
suggested species-specific differences in the mechanism of
action for these peptides. A G protein-coupled receptor,
GPCR147, for GnIH has recently been detected in human
hypothalamic neurons and pituitary gonadotropes, suggest-
ing clinical significance for GnRI peptides as adjuncts or
alternatives to GnRH analogs [23].
During the 1970s a search for non-steroidal factors that
regulate gonadotropin release led to the identification of
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dipitously activin, which increases FSH secretion. Both
inhibin and activin are members of the TGFβ superfamily
which appear to preferentially control the secretion of FSH
[6]. Activin acts as an autocrine/paracrine factor in the
anterior pituitary, and stimulates FSHβ gene transcription,
whereas inhibin, acting as an ovarian hormone, is inhibitory
[24]. Interestingly, another TGFβ family member, bone
morphogenetic protein-4, while having no effect on its own,
can modify activin- as well as GnRH-mediated gonadotro-
pin release by increasing mRNA of FSHβ [25].
Regulation of chorionic gonadotropin expression is less
well understood in part because no obvious placental signal
has been identified. Chorionic gonadotropins have been
found in only two groups of mammals, primates and
equids. When only human and horse chorionic gonadotro-
pins were well characterized, chorionic gonadotropin
expression was apparently exclusively placental in humans,
as a separate pituitary LH existed, whereas in the horse,
pituitary LH and placental CG were found to be comprised
of identical polypeptides. In the human, the CGβ gene
appeared to be derived from an ancestral LHβ gene, which
was located on the same chromosome and in the same gene
cluster. In the horse it was not known if a similar gene
duplication was followed by loss of one gene, as donkeys and
zebras also appear to possess only a LH/CGβ-like gene.
Recent studies of new world monkey CG may provide an
example of a path from separate LH and CG β-subunit genes
to a single LH/CGβ gene. The common marmoset (Callithrix
jacchus) was found to possess both LH and CG β-subunit
genes, however, only the CGβ gene was expressed in the
pituitary [26]. As the structural gene appeared normal, the
absence of expression probably reflects changes in regulatory
elements.Twoothernewworldmonkeys,thesquirrelmonkey
(Saimiri sciureus) and the owl monkey (Aotus trivirgatus)
were also reported to express only the CGβ gene in the
pituitary [27]. The potential for pituitary expression of CGβ
exists even in humans, as the presence of pituitary-derived
hCG was confirmed by its possession of pituitary-specific
sulfated glycans [28]. The mechanisms for loss of pituitary
expression of LHβ may emerge from studies of new world
monkeys.
3 Regulation of gonadotropin assembly and secretion
It is clear that initiation of events that lead to gonadotropin
gene expression rests at the level of secretagogues, and is
modulated by several factors. The biosynthesis of the
gonadotropin subunits can be considered in three steps.
Translation involving the cytoplasm and the endoplasmic
reticulum (ER), glycosylation and assembly taking place in
the ER, glycan remodeling, hormone packaging and secretion
taking place in the Golgi and secretogranins. Both subunits
are glycosylated, and the timing of glycosylation relative to
translation and transfer to the ER, as well as protein folding
andassemblyisstillunclear.Onlyveryearlyworkisavailable
on this topic. Rat LH subunits were reported to associate early
in the secretory pathway based on endoglycosidase H
sensitivity [29]. Ruddon’s lab reported assembly of hCG
subunits into heterodimer preparations possessing glycans
(Gn2M9Glc1 or Gn2M8 consistent with ER residency [30], as
did Magner and Weintraub for TSH [31].
Since the glycoprotein hormones are heterodimeric, it
could be anticipated that the expression patterns for both
genes that encode the α and β subunits are coordinated, lest
the production of either subunit be in vain without a partner
to form the heterodimer. Alternatively, excess of one
hormone can drive dimer formation. An early study showed
that in placenta the ratio of hCGα:hCGβ synthesis is 1.7:1
in early pregnancy and 12:1 at term [32]. In the pituitary,
this is difficult to evaluate because the α subunit synthesis
is associated with three β-subunits for FSH, LH and TSH.
Moreover, while hCGβ is often secreted as α free subunit,
LHβ,F S H β, and TSHβ are largely degraded intracellularly,
presumably because of improper folding. Failure to associate
with the β subunit results in aberrant glycosylation of the α
subunit. In the pituitary, the major difference is the O-
glycosylation of Thr
39, while in the placenta, increased N-
glycan branching replaces predominantly hybrid and bian-
tennary glycans with predominantly tri- and tetra-antennary
glycans. Unlike studies which examine gene expression,
using mRNA or promoter activation as readouts, an
understanding of the structural and cell biology of gonado-
tropin secretion has relied upon readouts of secretion rates
using pulse-chase analysis and formation of competent
hormones often interpreted in light of mutational analysis.
Crystal structures of the gonadotropins and the FSH
receptor provide a physical reference for such interpreta-
tions [33]. Figure 2 shows that the α and β subunits each
with three loops, orient in a head to tail 2-1/1-2 manner and
that the β subunit carboxy-terminal tail is wrapped around
the α subunit [34]. A terminal cysteine residue forms a
disulfide bond with the β-1 loop providing a latch for the
so-called “seat belt”. A nuance of the seat belt is that a
portion of it is gathered into a small cystine noose, whose
importance will become clear later in this paper. Although
glycoprotein α and β subunits can assemble in vitro, the
process is slow but can be accelerated by removal of the
carbohydrate in the second loop of the α subunit. This
observation squared with observations using pulse chase
studies, and so it was surmised that in vitro the association
of subunits relied on them to find a way for glycosylated
loop 2 of the α subunit to slide under the seat belt (no small
feat with carbohydrate attached), while in vivo, it was
possible that formation of the seatbelt clasp occurred
292 Rev Endocr Metab Disord (2011) 12:289–302following protein folding and assembly of the subunits into
the heterodimer.
The reasonable notion that in vivo seatbelt latching
occurred following subunit association remained largely
untested for 8 years after the crystal structure of hCG [35,
36] was published (Fig. 3). But shortly after the crystal
structure of FSH [37] was published, confirming the seat belt
motif as a general principle for the gonadotropins, subse-
quent studies were performed using mutagenesis and
antibody binding which suggested that threading of the α
subunit through the closed seat belt is the predominant
pathway for assembly [38]. The conundrum of how this can
occur was partially solved by a subsequent observation
involving the cystine noose referred to above. It turns out
that removal of the disulfide bond of this noose facilitates
assembly of the subunits into the heterodimer, in effect
letting out the gather of the seatbelt [39]. This mechanism
would necessarily be underpinned by a redox-coupled
system, but what this system is and whether it is regulated
is not clear at this time. The compact nature of the
GlcNAc2Man9Glc1 glycan may also facilitate threading as,
in vitro subunit association is most commonly studied using
hCG and various mammalian LH α subunits possessing
smaller, hybrid-type glycans (Fig. 4) attached to the αL2 Asn
(residue 52 in humans, 56 in most mammals). In contrast,
triantennary glycans, such as those attached to placental free
α subunit [40], prevent subunit association, while elimina-
tion of this glycan facilitates subunit association [41, 42]. In
fish, the mechanism of assembly appears to follow the less
efficient pathway where the subunits assemble first and then
the seat belt wraps around the α subunit and is latched [43].
The current thinking on this pathway to assembly of the
receptor binding competent heterodimer is as follows: Parts
of the β subunit amino terminus, reduced cystine knot, and
α subunit loops 1 and 3 dock; then the β subunit amino
terminus and the oxidized cystine knot (gathered again into a
noose) in complex with α subunit loop 2, form the stable
heterodimer [44]. The reader is referred to these elegant and
rather detailed studies for further information.
The secretion of the gonadotropic hormones has been
studied by pulse chase methods, followed by immunopre-
cipitation of the heterodimeric hormone and analysis of the
labeled subunits by gel electrophoresis. One of the first
differences in secretion noted, actually came from a compar-
ison of hCG and hLH, which are identical except for a β
subunit carboxyterminal extension that is O-glycosylated in
hCG and is absent in hLH. Using a cell line that exhibits
apical/basal secretion, it was shown that hCG was secreted
apically whereas LH was secreted basally [45, 46]. It has
since been determined that the apical secretion of hCG is
constitutive when compared to heterodimeric LH and that
the carboxy terminal tail of hCGβ, which is not present in
hLHβ, is necessary for the constitutive apical secretion [47].
When compared to LH, FSH was found to sort into both
apical and basolateral secretory compartments, and in LH,
the signal for basolateral secretion was found in the last
seven amino acids of the β subunit [48]. The secretion of
hFSH is constitutive, whereas LH secretion is induced by
Fig. 2 Three-dimensional struc-
tures for hCG and hFSH. The
structures were derived from pro-
tein databank files 1HRB and
1FL7, respectively, [106] and the
α-carbon backbones visualized
using the software package iMol
(http://www.pirx.com/iMol/).
Diagrams were exported from
iMol as encapsulated postscript
files and structural elements la-
beled using the software package
Adobe Illustrator. The subunits
a r ea s s o c i a t e di na na n t i - p a r a l l e l
manner with three Cys-knot
loops at opposite ends: βL1-
βL3-αL2 at one end and αL1-
αL3-βL2 at the other. The
receptor-binding elements are
located on the right side of each
model and consist of αL2, βL2,
the α-subunit C-terminus, along
with the seatbelt loop of which,
the Cys-noose, featured in the
subunit threading mechanism, is
most readily visible
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stretch of amino acids (LSGLLFL) in the LH β-subunit tail
[49]. In fact, FSH secretion could be switched from
constitutive to regulated by fusing that sequence to the
carboxyl terminal β-subunit tail of FSH [49, 50].
With regard to LH secretion, lipid rafts were recently
implicated in the mechanism for LH secretion when drugs
known to disrupt lipid rafts were shown to stimulate LH
secretion in vitro and in vivo [51]. The mechanism involved
appears to be controversial, as SNARES, reportedly
associated with rafts, are released, and in other systems
either stimulate or inhibit protein secretion.
4 Terminal glycosyl modification and therapeutic
gonadotropin preparations
One of the striking differences between FSH and LH, apart
from their β subunits, is that the majority of carbohydrates on
FSH are terminated with sialic acid whereas the vast majority
carbohydrates on LH are terminated in sulfate. In this regard,
hLH glycosylation is an exception, as 28% of the glycans are
terminated with sialic acid(Fig. 5)[ 52]. In the original model
for glycoprotein clearance, sialic acid prevented recognition
of the terminal galactose residues by Ashwell’s lectin, the
asialo-glycoprotein receptor (ASGP-R) [53], thus prolonging
hFSH half-life in the blood. However, this was consistent
only with α2–3 linked sialic acid residues found in
hCG, which was used in the pioneering Ashwell
experiments [54]. Interestingly, the ASGP-R did not
appear to be involved in clearance of sialylated hCG, as
saturating the receptor with desialylated glycoproteins had
no effect on native hCG clearance, while slowing asialo-
hCG clearance [55]. Subsequently, Baenziger and col-
leagues demonstrated that α2-6 linked sialic acid did not
prevent galactose residue recognition by the ASGP-R
(Fig. 6), which is relevant for hFSH and hLH, as they
possesses both α2-3 and α2 - 6l i n k e ds i a l i ca c i dr e s i d u e s
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Fig. 3 Mechanisms for hCG subunit association. A. Classic tethering
mechanism proposed by Ruddon and colleagues [107]. The α subunit
is folded and ready for association. Partially folded hCGβ gains
dimerization competency when the 93–100 disulfide bond forms.
Subunits dock, forming inactive α/β dimer. Active conformation
forms and formation of 26–110 disulfide stabilizes functional hCG. B.
Alternative threading mechanism proposed by Moyle and colleagues
[38, 39, 43, 44]. The hCGβ 26–100 seatbelt loop disulfide bond has
formed, and the 93–100 disulfide opens, thereby enlarging the seatbelt
loop. The α subunit with a compact glycan threads through the
enlarged seatbelt loop, forming inactive α/β dimer. Active hCG
conformation in αL2 is established and 93–100 disulfide bond
reforms. To simplify the diagrams, only the α subunit N-glycans are
indicated as outlines of the GlcNAc2Man9Glc1 oligosaccharide
294 Rev Endocr Metab Disord (2011) 12:289–302[56]. Moreover, in the female rat pituitary, estrogen
feedback has been shown to regulate the expression of
α2-3-sialyltransferase (ST3Gal III) [57]. In contrast, in the
male α2-6-sialyltransferase (ST6Gal I) appears to be under
Fig. 4 Models of N-glycans
found attached to αLoop2
Asn
52 (human numbering). A.
Top view of glycans found on
hCGα under various conditions.
B. Side view of the same gly-
cans. The β(1–4)-linked Man
residue that initiates branching
is labeled in both views of each
structure. C. Diagrams of glycan
structures showing monosac-
charide residues and linkages for
glycans in A and B. Oligosac-
charide models were built with
the Woods Group (2005-2011)
Glycam Web Carbohydrate
Builder. Complex Carbohydrate
Research Center, University of
Georgia, Athens, GA. (http://
www.glycam.com) Structure 1,
high mannose glycan GlcNAc2-
Man9Glc1 found in ER on fold-
ing proteins; structure 2, typical
urinary hCG-derived, hCGα
Asn
52 hybrid-type N-glycan;
structure 3, triantennary glycan,
such as those associated with
urinary free hCGα
Fig. 5 Glycosylation patterns for human gonadotropins. Site-specific
glycosylation patterns are shown for each hormone. The subunit
polypeptides are indicated as solid bars, with the glycosylated Asn or
Ser residues indicated by numbers below each bar. The most abundant
glycan found at each site is shown along with its relative abundance, if
known. The hCG and hLH glycans were determined by nmr [52, 108],
therefore, monosaccharide sequence and linkage were unambiguous.
The hFSH glycans were determined by glycopeptide mass spectrom-
etry [62, 67] leading to ambiguities in branch location and sialic acid
linkages, as indicated. The α-subunit glycans are shown without core
fucose, as the abundance of this monosaccharide residue is found in
10% or fewer α-glycans. The β-subunit glycans are shown with core
fucose, as 80–90% of β-glycans possess this residue. The O-glycan
distribution is as determined by mass spectrometry of tryptic
glycopeptides [97]. Glycan diagrams follow the Oxford Glycobiology
Institute format [109] except that 1–6 and 2–6 bonds are indicated by
a longer line to emphasize that the monosaccharide is attached to a
potentially more flexible linkage via an exocyclic carbon atom, rather
than to a ring carbon (see Key inset). Note that sialic acid is attached
only via α2-3 linkages in hCG, but both α2-3 and α2-6 linkages are
found in hLH and hFSH (although not shown for hFSH glycopeptides,
it is well known from studies involving oligosaccharides)
Rev Endocr Metab Disord (2011) 12:289–302 295gonadal regulation, but not α2-3-sialyltransferase [58]. If
gonadotrope expression of these enzymes is regulated by
estrogen, then one potential mechanism for increasing the
clearance rate of FSH may involve increasing the relative
abundance of α2-6-linked sialic acid terminating FSH
glycans as compared with α2-3-linked sialic acid. The sulfate
on the other hand decreases the half life of LH providing for
more fine control of blood levels in most species [59].
Although it seemed reasonable to hypothesize that the
sulfation of terminal carbohydrate may in some way direct
LH to the inducible secretory pathway, inhibition of sulfation
did not shunt LH to the constitutive pathway [60]. One
problem with this hypothesis is the fact that FSH from non-
human mammals is decorated with 13–40% sulfated glycans
[56, 61, 62]. Thus, human FSH represents a special case in
that sulfated glycans represent less than 10% of the total
glycan population [56, 62]. Moreover, hLH possesses 22–
39% sialylated glycans at each glycosylation site, with sialic
acid linked both α2-3 and α2-6. Human LH clearance more
closely resembles that of hFSH than LH from other
mammalian species because it ends up in the urine while
more highly sulfated LH preparations, such as pLH, do not
[63].
Pharmaceutical-grade recombinant human gonadotropins
are expressed in Chinese hamster ovarian cells (Table 1),
and their glycosylation reflects glycosyl transferase expres-
sion in that cell line. MALDI-TOF-MS and ESI-MS, as
well as MS/MS analysis of glycans derived from recombi-
nant hLH, hFSH, and hCG preparations produced by EMD
Serono, revealed only sialylated glycans associated with
these gonadotropin preparations [64]. The most abundant
glycans were biantennary, although lesser amounts of tri-,
tetra-, and even penta-antennary glycans were also detected.
For hCG and hLH, the natural forms of these hormones are
largely decorated with biantennary glycans. For hLH, the
absence of sulfate and α2-6-linked sialic acid [65] would
appear to eliminate both liver clearance mechanisms,
thereby prolonging hLH survival in the serum. Longer
halflife would not seem to affect clinical use of hLH, as
hCG, with an even longer halflife, is typically substituted
for hLH to induce ovulation. Moreover, one clearance study
in primates indicated only a modest reduction in recombi-
nant hLH clearance as compared with pituitary hLH [66].
This result is consistent with an in vivo imaging analysis of
the clearance of pLH, a highly sulfated gonadotropin
preparation, in rats [63]. The labeled hormone was only
transiently associated with the liver during the distribution
phase, and clearance appeared to take place largely in the
kidneys. For recombinant hFSH, the abundance of trianten-
nary and tetraantennary glycans appears to be higher than
observed in recombinant hLH and hCG preparations, but
lower than in pituitary hFSH [64]. The distribution of
glycans on the FSH molecule may be important for
biological activity. Glycopeptide mass spectrometry, which
potentially could simultaneously characterize all four FSH
glycosylation sites, provided detailed information only for
two sites, αAsn
52 and βAsn
7 [62, 67]. Limited data hinting
at preferential attachment of highly branched glycans at
αAsn
78 need confirmation [67].
The focus on FSH isoforms for the last 38 years has
emphasized terminal charged residues on the associated
glycans because sulfate and sialic acid residues are
negatively charged and the existence of charge heterogene-
ity is attributed to these residues. However, FSH glycosyl-
ation variations also include the absence of one or both N-
glycans and branching of the glycans, as well as terminal
sialylation or, to a lesser extent, sulfation. Thus, 90% of
horse (e)FSHβ lacks Asn
7 glycans, while 13–54% of
pituitary hFSH preparations lack both hFSHβ glycans
[68]. The latter pattern may also exist in two other primate
species, Rhesus macaque (Macaca mulatta) and Japanese
Fig. 6 Asialoglycoprotein ligands. Based on similarities between the
mannose binding protein and ASGPR carbohydrate binding domains,
the latter is expected to bind hydroxyls attached to Gal carbons 3 and
4 (arrow, see p 184 [110]). A. The α2-6-linked sialic acid does not
block access to these. B. The α2-3-linked sialic acid blocks access to
both hydroxyls by replacing the C-3 hydroxyl with a glycosidic bond
and potentially steric hindrance of the C-4 hydroxyl
Hormone Trade Name Manufacturer Cell Line
FSH Gonal-f® EMD Serono
a Chinese Hamster Ovary (CHO) cells
FSH Follistim® Merck
b CHO cells
LH Luveris® EMD Serono CHO cells
CG Ovidrel® EMD Serono CHO cells
Table 1 Recombinant gonado-
tropin preparations
aFormerly Serono
bFormerly Organon
296 Rev Endocr Metab Disord (2011) 12:289–302macacque (M. fuscata). While LH glycans are typically,
hybrid or complex, biantennary [52], FSH largely lacks
hybrid glycans, and possesses complex: biantennary, tri-
aantennary, and tetraantennary glycans [56, 62, 69]. In
hFSH, triantennary and tetraantennary glycans amplify
heterogeneity as mono-, di-, and tri-sialyl variants of
triantennary and tetraantennary glycans are found [62].
Terminal sialylation has been assumed to produce FSH
isoforms, however, mass spectrometry of isoform glycans
revealed a great deal of similarity in the glycan populations
of FSH isoforms [67]. While two studies have examined
expression of two sialyl transferases [57, 58], understanding
sialylation is complicated by the large number of sialyl-
transferase isoforms that exist in mammals. For example,
there are 20 sialyltransferase genes in the mouse and human
genomes [70]. These are arranged into four classes based
on sialic acid linkage to the underlying glycan and substrate
specificity [71]. The α2,6-sialyltransferases ST6Gal I-II
and the α2,3-sialyltransferases ST3Gal III, IV, and VI are
capable of attaching sialic acid to terminal Gal or GalNAc
residues in gonadotropin N-glycans. While pituitary gona-
dotropins possess both α2,3- and α2,6-linked sialic acid,
placental hCG and recombinant gonadotropins produced in
Chinese hamster ovarian cells possess only α2,3-linked
sialic acid. Recent developments in mass spectrometry
procedures should facilitate identification of sialyltrans-
ferases involved gonadotropin synthesis. Modification of
sialylated glycans with 4-(4,6-dimethoxy-1,3,5-triazin-2-
yl)-4-methylmorpholinium chloride not only stabilizes
sialylated glycans for analysis, but also distinguishes α2,3
from α2,6 linked sialic acid [72]. The relatively modest
amounts of hormone needed,10 μg, makes it feasible to
evaluate the effects of modifying sialyltransferase expres-
sion on gonadotropin glycosylation. However, future
\studies should also examine oligosaccharyltransferase,
which initiates N-glycosylation, and the GlcNAc trans-
ferases responsible for complex glycan branching.
5 Regulation of N-glycosylation and branching
N-glycosylation is initiated by an 8-subunit enzyme complex
called oligosaccharyl transferase (OST) that transfers a
preformed precursor oligosaccharide from dolichol pyrophos-
phate to the nascent glycoprotein chain [73, 74]. Partially N-
glycosylated forms of recombinant hCG and pituitary FSH
have been reported, while LH and TSH appear to be
completely glycosylated, as is the common α subunit. The
all-or-none N-glycosylation of hFSHβ, appears to be the
result of selective inhibition of OST activity, as the
complementary hFSHα subunit is quantitatively glycosy-
lated [75]. In yeast there are 9 genes for 8 OSTsubunits [76].
Mammalian equivalents of the yeast subunit genes have been
identified [74] as well as two isoforms of the catalytic
subunit,STT3[77]. Immunopurified yeast OSTappears to be
a dimer based on blue gel electrophoresis in which the major
band was estimated to be a 500 kDa complex, while protein
sequences predicted a 250 kDa molecular weight [78]. The
yeast enzyme appears to be regulated by PKC [79], which is
interesting because PKC is the primary signaling pathway
activated by GnRH. The challenge is to understand how
glycosylation of the FSHβ subunit is selectively inhibited,
while permitting full glycosylation of the common α subunit,
not to mention the LHβ subunit, within the same cellular
compartment. One possible mechanism could involve the
use of different OST isoforms.
Some lessons have been learned from studies in yeast. Two
OST isoforms have been identified in yeast that differ in one
subunit, Ost3p or Ost6p [80]. Mammalian homologs for both
subunits are, N33 and IAP, respectively [81]. Mammalian
OST isoforms also differ in the nature of the putative catalytic
subunit STT3 [81]. STT3A appears to be involved in co-
translational N-glycosylation, while STT3B appears to be
involved in post-translational N-glycosylation [77]. Possible
posttranslational glycosylation of FSH subunits might occur,
as a low MW form was detected during pulse-chase
expression of hFSH, that chased into the high MW form
over time [82]. Thus, it may be possible to inhibit FSHβ
glycosylation by knocking down STTB expression. Each of
the yeast OST isoforms is associated with a specific
translocon; OST possessing Ost3p with Sec61 and OST
possessing Ost6p with Ssh1p [80]. Yeast translocons differ in
the specificity of the signal peptides that they accept. Sec61 is
necessary for cell viability and accepts a wider range of signal
peptides while Ssh1p is less essential and accepts signal
peptides with high hydrophobic character. Analysis of signal
peptides for the common α subunit and hFSHβ with the
DNA Star Protean software revealed a hydrophilic N-
terminus in the first 8 residues of the common α subunit
signal peptide and a hydrophobic N-terminus in the first 9
residues of the FSHβ signal peptide. This suggests a strategy
of swapping leader sequences between the α and FSHβ
subunits, however, a mammalian homolog of Ssh1p does not
appear to exist. An uncharacterized homolog of Sec61
(accession number D3ZEH3) does exist in the rat that is the
same size and is 93% identical to Sec61. In principle, mass
spectrometry should permit analysis of partially glycosylated
FSH variants, however, oligosaccharide heterogeneity, partic-
ularly that associated with the common α subunit obscures
FSHβ isoforms lacking one or more N-glycans [68].
N-glycosylation in the ER is a highly conserved process
with defined intermediates involved in protein folding, exit
of folded protein to the Golgi, and the retrograde transport
of unfolded proteins to the cytoplasm for proteosome-
mediated degradation [83]. Glycan diversity is subsequently
generated in the Golgi, and glycan branching is a major
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transferases, which are characterized by the core mannosyl
residue and linkage of the GlcNAc residue attached to the
pentasaccharide core. All but the bisecting GlcNAc residue,
which is attached β(1–4) to the β(1–4)-linked Man residue,
can be extended by other glycosyltransferases to yield the
mature branches of the glycan. Based on the existence of
largely hybrid and biantennary glycans attached to hCG and
hLH, along with triantennary and tetraantennary glycans
attached to hFSH, the following GlcNAc transferases modify
gonadotropin glycans: MGAT1 (GlcNAc transferase I),
MGAT2 (GlcNAc transferase II), MGAT3, (GlcNAc trans-
ferase III), MGAT4 (GlcNAc transferase IV), and MGAT5
(GlcNAc transferase V). LH and hCG glycans are products
of GlcNAc transferase I alone, or both I and II, as only
hybrid or biantennary glycans decorate these hormones. In
the mouse and human genomes there are single genes for
GlcNAc transferases I, II, and III, while there are 2 isoforms
for both GlcNAc transferases IV and V. Loss of GlcNAc
transferase I in the whole mouse is embryonic lethal [84]a n d
oocyte-specific knock out leads to a reduced ovulation rate
[85]. Loss of GlcNAc transferase II in mice is often
embryonic lethal, but can be studied in some genetic
backgrounds, which provide a model for the human disease
congenital disorder of glycosylation type IIa [86]. Male mice
with this disorder are sterile due to spermatogenic failure,
while humans exhibit testicular atrophy. Loss of GlcNAc
transferase III appears to inhibit growth factor signaling [87]
and can counteract the metastatic properties of tumor cells
expressing GlcNAc transferase V [88]. Both GlcNAc trans-
ferases IV and V are responsible for tri- and tetra-antennary
glycan synthesis. These glycans appear to interact with
galectins to prolong surface residence of membrane glyco-
proteins, which may be relevant to FSH, as recently galectin-
1 was detected in porcine granulosa cells. Moreover,
galectin-1 inhibited FSH-stimulated steroidogenesis in these
cells [89]. GlcNAc transferase IVexists as two isoforms IVa
and IVb. The former is normally expressed in the digestive
system, while the latter is more broadly expressed. However,
when the IVb gene was knocked out, compensatory
expression of the IVa gene appeared to largely make up for
the loss of the former [90]. Mice deficient in MGAT5Awere
reported in 2002, and exhibited susceptibility to autoimmune
disease, reduced cancer progression, and a behavioral defect
[91]. Ayearlaterthe existence ofasecondisoform,MGAT5B
was reported [92]. Expression of the former is widespread,
while the latter is restricted to neural tissue and the testis.
Thus, the full ramifications of this transferase have not yet
been examined. Because contemporary mass spectrometry
techniques can analyze glycans derived from as little as
10 μg recombinant gonadotropin, it is feasible to monitor the
results of modifying GlcNAc transferase activities on the
glycan populations associated with these hormones.
Hyperglycosylated hCG is one of several variants of this
clinically and diagnostically valuable gonadotropin, and is
associated with early pregnancy and cancer [4, 93]. Early
pregnancy hyperglycosylated hCG is secreted by extravi-
lous cytotrophoblast cells, and not by the syncytiotropho-
blast [94]. It appears to act in an autocrine/paracrine manner
to promote cytotrophoblast invasion of the uterus [95].
Typically, hyperglycosylated hCG is identified in clinical
studies by the binding of monoclonal antibody B152 that is
dependent on the presence of a core type-2 O-glycan at
Ser132 instead of the usual disialylated core type-1 glycan
(Fig. 5, illustrates these glycan structures at positions 121
and 132, respectively, for normal pregnancy hCG). Reduced
hyperglycosylated hCG is associated with increased risk for
early pregnancy loss [96]. Glycosylation site-specific
differences in glycan structure between tumor-derived
hyperglycosylated hCG and normal pregnancy hCG β-
subunits have been defined by mass spectrometry [97]. A
site-specific increase in the abundance of tri-antennary
glycans over bi-antennary glycans was observed at βAsn
30,
but not βAsn
13.A sA s n
30 glycans are involved in signal
transduction, this may have functional significance, since
hyperglycosylated hCG has been shown to be impaired in
its steroidogenic potency, yet promotes cell invasion by
cytotrophoblasts [95]. On the other hand, the increased
abundance of fucosylated glycans at Asn
13, may also
influence function, as lentil lectin-bound TSH was reported
to exhibit biased agonism, activating both cAMP and PLC
pathways, while unbound TSH activated only the cAMP
pathway [98]. Mass spectrometry also better defined the
differences in O-glycosylation, revealing changes from core
type 1 to core type 2 glycans at Ser132 and Ser138, as well
as increased glycosylation site occupancy at Ser127 [97].
6 Glycosylation and therapeutic function
The design and implementation of glycoprotein hormones for
therapeutic purposes in part relies on and is limited by their
structural requirementsfor biosyntheticprocesses,inparticular
the regulation of glycosylation [99]. The heterogeneity of
gonadotropin glycosylation has led to many theories about
the relative role of differentially charged isoforms and
concerns about their pharmacological properties [100–102].
Gonadotropin utility in humans and more recently in
domestic animals [103] has encouraged thinking about
strategies to enhance half-life and whether glycosylation
plays roles in biological activity apart from circulatory half-
life. Emerging strategies for homogenous glycosylation of the
subunits could potentially allow for the preparation of
completely homogenously glycosylated gonadotropins, which
would be an improvement of the existing formulation [104].
Indeed the finding that glycosylation of the β subunit of
298 Rev Endocr Metab Disord (2011) 12:289–302hFSH varies with age has prompted thinking that new forms
of therapeutic gonadotropins should include more di-
glycosylated as in young women [68]. Thus cycling young
women have a greater proportion of heterodimeric FSH,
which is not glycosylated at all on the β subunit, whereas
menopausal women have a higher proportion of FSH which
is glycosylated on all four sites [68]. It is reasonable to
assume that there will be differences in biological activities of
the tetra and di-glycosylated FSH because already there is
evidence for biased agonism with other glycoform variants of
hFSH [105].
7 Future directions
Current second generation gonadotropin preparations incor-
porate changes in the protein moieties to increase stability by
expressingtheαandβsubunitsassingle-chainmoleculesand
toincrease survivalin the circulation byaddition ofthe hCGβ
C-terminal peptide. The control of transcription of genes
encoding proteins that are involved in the post-translational
modifications of the gonadotropins, although more compli-
cated, seems warranted. Little is known about how secreta-
goguessuchasGnRHorsteroidsaffecttheirexpression.Little
is known how altering the activities of specific glycosyltrans-
feraseswillaffecttherelativeabundanceofadesiredglycanat
various glycosylation sites in the protein. For example, if
GnTase IV is overexpressed, will there be an increase in
triantennary glycans at all 4 sites in FSH? Will LH glycans
become predominantly triantennary or will they remain
largely biantennary? Oligosaccharide mass spectrometry can
address the relative abundance for the total glycan population.
Once desired glycan abundance increases, a more demanding
approach will be needed to define glycosylation at individual
sites. Here, mass matching of glycopeptides combined with
detailed analysis of total oligosaccharide preparations would
probablyprovidesufficientdetailfordevelopmentalstudies.If
uniformlyglycosylatedgonadotropinscould beprepared, then
experiments to compare relative activities are readily per-
formed and could be used to design more effective gonado-
tropin preparations for clinical use.
Overexpression of GnTases would be useful to make
recombinant hyperglycosylatedhCG, which would be valuable
as a standard for diagnostic assays for early pregnancy loss.
The literature largely describes tumor-associated hyperglyco-
sylated hCG and glycosylation differences exist. Detailed
characterization of early pregnancy hyperglycosylated hCG
Replacement therapy with hyperglycosylated hCG might
become possible when low levels of this hormone are detected,
once obvious difficulties with administration of a paracrine
factor are overcome. It is possible intrauterine rather than
systemic administration would be effective. The potential to
stimulate cell invasion would have to be carefully evaluated
and antagonists developed. Differences in glycosylation
between young and menopausal women certainly suggests
major differences in the post-translational modification path-
ways. Future studies should address whether di- and tetra-
glycosylated hFSH are effective as isolated glycoforms. As
physiological samples almost invariably contain both glyco-
forms, normal reproductive function may require the presence
of both glycoforms. Preparation of individual glycoforms is
necessary even if both are needed, as it would be possible to
vary the ratios of the two forms and test their efficacy. For
example, in IVF protocols, it might be helpful to vary the ratio
of the two forms during the period of hyperstimulation to
reflect the physiology of younger, more fertile women.
Identification of the protein, which recognizes the seven amino
acid sorting signal in hLH, and directs it to the induced
secretion pathway would be of interest.
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